2001至2013年美国髓母细胞瘤发病与生存趋势
基于美国中央脑肿瘤注册库(CBTRUS)2001至2013年数据,分析髓母细胞瘤年龄调整发病率及年度变化百分比,并用SEER注册库计算相对生存率。结果显示总体发病率相对稳定,1至4岁患者发病率最高,10至14岁患者发病率上升(APC=3.2,95%CI 0.6,5.8),男性发病率高于女性(0.16 vs 0.12),但1岁以下无性别差异且5年相对生存较差。
要点
- 2001至2013年髓母细胞瘤总体发病率相对稳定。
- 10至14岁患者发病率上升,APC=3.2(95%CI 0.6,5.8)。
- 1岁以下男女发病率相同且5年相对生存较差。
核心结论
- 2001至2013年髓母细胞瘤总体发病率无变化。
- 1岁以下男女患者发病率相同,且与其他年龄相比5年相对生存较差。
- 数据中非显著趋势提示髓母细胞瘤发病和生存存在种族差异。
研究设计与样本
- 分析美国中央脑肿瘤注册库(CBTRUS)2001至2013年数据。
- 按年龄、性别和种族计算年龄调整发病率(IR)及年度变化百分比(APC)及95%置信区间。
- 使用SEER注册库(CBTRUS数据的子集)按年龄、性别和种族计算相对生存率,并用Kaplan-Meier和Cox比例风险模型分析生存差异。
主要发现
- 2001至2013年髓母细胞瘤发病率相对稳定,2001至2009年APC=2.2(95%CI 0.8,3.5),2009至2013年APC=-4.1(95%CI -7.5,-0.6)。
- 诊断时1至4岁患者发病率最高,但10至14岁患者2000至2013年发病率上升(APC=3.2,95%CI 0.6,5.8)。
- 男性年龄调整发病率高于女性(男性0.16 vs 女性0.12),但1岁以下患者例外。
- 与白人相比,黑人发病率非显著增加(APC=1.7,95%CI -0.4,4.0),死亡风险非显著增加(生存风险比=0.74;p=0.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Population-based data examining recent epidemiological trends in medulloblastoma, the most common pediatric brain malignancy, are limited. Therefore, we sought to examine recent population-level trends in medulloblastoma incidence and survival. Central Brain Tumor Registry of the United States (CBTRUS) data were analyzed from 2001 to 2013. Age-adjusted incidence rates (IR) and annual percent changes (APCs) with 95% confidence intervals (CI) were calculated by age, sex, and race. Relative survival rates were calculated by age, sex, and race using Surveillance, Epidemiology and End-Results (SEER) registries; subsets of CBTRUS data. Kaplan-Meier and Cox proportional hazards models were used to examine survival differences. Medulloblastoma incidence remained relatively stable from 2001 to 2013, with minor fluctuations from 2001 to 2009 (APC = 2.2, 95% CI 0.8, 3.5) and 2009-2013 (APC = -4.1, 95% CI -7.5, -0.6). Incidence was highest in patients aged 1-4 years at diagnosis, but patients aged 10-14 years showed increased incidence from 2000 to 2013 (APC = 3.2, 95% CI 0.6, 5.8). Males displayed higher IR relative to females (males: 0.16 vs. females: 0.12), except in patients <1 year-old. Compared to Whites, Blacks displayed a non-significant increase in incidence (APC = 1.7, 95% CI -0.4, 4.0) and in mortality risk (hazard ratio for survival = 0.74; p = 0.09). The current study reports no overall change in medulloblastoma incidence from 2001 to 2013. Male and female patients <1 year-old had equal medulloblastoma incidence rates and poor 5-year relative survival compared to other ages. Non-significant trends in the data suggest disparities in medulloblastoma incidence and survival by race. Thus, analysis of tumor-specific trends by demographic variables can uncover clinically informative trends in cancer burden.
引用
- Khanna V, Achey RL, Ostrom QT, et al. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol. 2017. PMID: 28828582. doi:10.1007/s11060-017-2594-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。